{
    "prompt": "MANDATORY SPONSOR INPUTS FOR STUDY PROTOCOL GENERATION\nSponsor Name FADOI /BMS/PFIZER\nStudy Acronym (if available):  CARAVAGGIO Study\nTested IMP :Apixaban\nComparative drug: Dalteparin\nStudy Type Interventional\nSe Study Type = Interventional:\nInterventional Study Phase Phase IIIb\nStudy Design International, multicenter, Prospective Randomized Open Blinded End-point (PROBE), where both patients and investigators are aware of the treatment assignments, but the outcome assessment is blindedactive-controlled, event-driven, Phase IIIB clinical study comparing the efficacy and safety of Apixaban to the SOC Dalteparin in for the treatment of venous thromboembolism in patients with cancer.\nAim of the study: The aim of this study is to assess whether oral apixaban is non-inferior to the subcutaneous low molecular weight (LMWH) dalteparin for the treatment of newly diagnosed proximal deep vein thrombosis (DVT) and/or pulmonary embolism (PE) in patients with cancer.\nTarget Disease: VTE (DVT/PE) in cancer patients\nType of Randomization: Patients will be randomized on a 1:1 basis (permuted blocks of four) to receive either apixaban or dalteparin in an open-label fashion.\nRandomization should be centralized and stratified by:\n1) symptomatic vs. unsuspected VTE\n2) active cancer vs. history of cancer\nTested drugs and dosages \nApixaban group: orally administered, at the dose of 10 mg bid for 7 days, followed by 5 mg bid (total period of treatment: six months)\nDalteparin group: subcutaneously administered, at a dose of 200 IU/kg SC o.i.d for 1 month. Thereafter, dalteparin will be administered at a dose of 150 IU/kg o.i.d. for 5 months (total period of treatment: six months). The maximum daily dose allowed for dalteparin is 18,000IU.\nApixaban 5mg will be supplied by the Promoter as film-coated tablets.\nDalteparin will be supplied by the Promoter as single-use pre-filled syringes.\nStudy Scheduled Patient’s Visits\nThe study should foresee the following scheduled visits: at enrollment, at 4 weeks, at 3 months, at 6 months, at the end of study treatment whenever it occurs, and at 7 months from randomization.\nAdditional visits will be performed if new symptoms and/or signs of VTE or major bleeding develop. A clinical examination and objective tests will be performed if the patient develops symptoms or signs suggestive of recurrent VTE.\nStudy Objectives \nPrimary efficacy outcome:\nobjectively confirmed recurrent VTE occurring during the study period, that means the composite of:\n• proximal DVT of the lower limbs (symptomatic or unsuspected)\n• DVT of the upper limb (symptomatic)\n• PE (symptomatic or unsuspected)\nSecondary efficacy outcomes:\n• the individual components of the primary efficacy outcome;\n• symptomatic recurrence of VTE;\n• all cause death;\n• the composite of primary efficacy outcome plus major bleeding;\n• the composite of primary efficacy outcome plus major bleeding plus all cause death;\n• the composite of primary efficacy outcome plus all cause death;\n• any major cardiovascular event, fatal or non-fatal (including acute myocardial infarction or ischemic stroke);\n• all venous thromboembolic events (including splanchnic vein thrombosis and cerebral vein thrombosis);\n• Quality of life (QoL) according to Anti-Clot Treatment Scale (ACTS) \nSafety Study Outcomes:\nPrimary safety outcome is major bleeding, defined (as per ISTH guidelines), as acute clinically overt bleeding associated with one or more of the following:\n• decrease in hemoglobin of 2 g/dl (1.2 mmol/L) or more;\n• transfusion of 2 or more units of packed red blood cells;\n• bleeding that occurs in at least one critical site [intracranial, intra-spinal, intraocular (within the corpus of the eye; thus, a conjunctival bleed is not an intraocular bleed), pericardial, intra-articular, intramuscular with compartment syndrome, or retroperitoneal];\n• bleeding that is fatal;\n• bleeding that necessitates acute surgical intervention\nSecondary safety outcomes include:\n• Clinically relevant non-major bleeding event defined as acute clinically overt bleeding that does not meet the criteria for major and consists of:\n• any bleeding compromising hemodynamics;\n• spontaneous hematoma larger than 25 cm2, or 100 cm2 if there was a traumatic cause;\n• intramuscular hematoma documented by ultrasonography;\n• epistaxis or gingival bleeding requiring tamponade or other medical intervention or bleeding from venipuncture for >5 minutes;\n• hematuria that was macroscopic and was spontaneous or lasted for more than 24 hours after invasive procedures;\n• hemoptysis, hematemesis or spontaneous rectal bleeding requiring endoscopy or other medical intervention;\n• or any other bleeding considered to have clinical consequences for a patient such as medical intervention,\nthe need for unscheduled contact (visit or telephone call) with a physician, or temporary cessation of a study drug, or associated with pain or impairment of activities of daily life.\n• Clinically relevant bleeding defined as the composite of major and clinically relevant non-major bleeding\n• Permanent early discontinuation of study drug due to safety reasons\nMaximum Sample Size for each arm\nLess than 600 patients for each treatment group\nRecommended Inclusion Criteria\nAge > 18 years\nBoth Genders\nSigned Informed Consent\nConsecutive patients with a newly diagnosed, objectively\nconfirmed:\n• symptomatic or unsuspected, proximal lower-limb DVT\nor\n• symptomatic PE or\n• unsuspected PE in a segmental or more proximal pulmonary artery.\nAny type of cancer (other than basal-cell or squamous-cell carcinoma of the skin, primary brain tumor or known intracerebral metastases and acute leukemia) that meets at least one of the\nfollowing:\n• Active cancer defined as diagnosis of cancer within six months before the study inclusion, or receiving treatment for cancer at the time of inclusion or any treatment for cancer during 6 months prior to randomization, or recurrent locally advanced or metastatic cancer.\n• Cancer diagnosed within 2 years before the study inclusion (history of cancer).\nRecommended Exclusion Criteria\nage <18 years\nECOG Performance Status III or IV;\nlife expectancy of less than 6 months;\nrelated to anticoagulant treatment:\nadministration of therapeutic doses of LMWH, fondaparinux, or unfractionated heparin (UFH) for more than 72 hours before randomization;\n3 or more doses of a vitamin K antagonist before randomization;\nthrombectomy, vena cava filter insertion, or thrombolysis used to manage the index episode;\n indication for anticoagulant treatment for a disease other than the index VTE episode;\nconcomitant use of strong inhibitors or inducers of both cytochrome P-450 3A4 and P-Glycoprotein ;\nrelated to bleeding risk:\nconcomitant thienopyridine therapy (clopidogrel, prasugrel, or ticagrelor) or aspirin over 165 mg daily or dual antiplatelet therapy;\nactive bleeding or high risk of bleeding contraindicating anticoagulant treatment\nrecent (in the last 1 month prior to randomization) brain, spinal or ophthalmic surgery\n hemoglobin level lower than 8 g/dL (5.0 mmol/L) or platelet count <75x109/L or history of heparin-induced thrombocytopenia;\ncreatinine clearance < 30 ml /min based on the Cockcroft Gault equation;\nacute hepatitis, chronic active hepatitis, liver cirrhosis; or an alanine aminotransferase level 3 times or more and/or bilirubin level 2 times or more higher the upper limit of the normal range;\nuncontrolled hypertension (systolic BP> 180 mm Hg or diastolic BP > 100 mm Hg despite antihypertensive treatment);\nstandard criteria:\n bacterial endocarditis;\nhypersensitivity to the study drugs or to any of their excipients;\npatients participation in other pharmaco therapeutic program with an experimental therapy that is known to effect the coagulation system.\nwomen of childbearing potential (WOCBP) who do not practice a medically accepted highly effective contraception during the trial and one month beyond. Highly effective contraception methods are:\na. combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation\nb. progestogen-only hormonal contraception associated with inhibition of ovulation\nc. intrauterine device (IUD)\nd. intrauterine hormone-releasing system (IUS)\ne. bilateral tubal occlusion\nf. vasectomized partner\ng. sexual abstinence ;\npregnancy, or breast feeding\nany condition that, as judged by the investigator, would place the subject at increased risk of harm if he/she participated in the study.\n",
    "output": "## 10.6 Appendix 6: Liver Safety: Suggestions and Guidelines\n\n## for Liver Events\nPatients will be excluded from the study if they have acute hepatitis, chronic active hepatitis,\nor liver cirrhosis.\nPatients will also be excluded if their alanine aminotransferase (ALT) level is ≥3 times the\nupper limit of normal (ULN) and/or their bilirubin level is ≥2 times the ULN.\nApixaban will be contraindicated in patients with hepatic disease associated with\ncoagulopathy and a clinically relevant bleeding risk. It will not be recommended for patients\nwith severe hepatic impairment and should be used with caution in those with mild or\nmoderate hepatic impairment (Child Pugh A or B).\nLiver function testing will be performed prior to initiating apixaban.\n# 10.7 Appendix 7: Medical Device AEs, ADEs, SAEs,\n# SADEs, USADEs and Device Deficiencies: Definitions\n# and Procedures for Recording, Evaluating, Follow-up,\n# and Reporting in Medical Device Studies\nThe definitions and procedures detailed in this appendix will be in accordance with ISO\n14155 and the European Medical Device Regulation (MDR) 2017/745 for clinical device\nresearch (if applicable).\n## 10.7.1 Definition of Medical Device AE and ADE\nA medical device AE will be any untoward medical occurrence in a clinical study participant,\nuser, or other person, temporally associated with the use of a study device.\nAn adverse device effect (ADE) will be an AE related to the use of an investigational\nmedical device, including events from use error or malfunction.\n## 10.7.2 Definition of Medical Device SAE, SADE and USADE\nA Medical Device SAE will be an AE that led to death, serious deterioration in health (life-\nthreatening illness, permanent impairment, hospitalization), or fetal distress/death/\ncongenital abnormality.\nAn SADE will be an ADE that has resulted in any of the consequences characteristic of an\nSAE, or a device deficiency that might have led to an SAE.\n•\n•\n•\n•\n•\n•\n•\n•\n•\nAn USADE will be an SADE that, by its nature, incidence, severity, or outcome, has not\nbeen identified in the current version of the risk analysis report.\n## 10.7.3 Definition of Device Deficiency\nA device deficiency will be an inadequacy of a medical device with respect to its identity,\nquality, durability, reliability, safety, or performance. This will include malfunctions, use\nerrors, and inadequate information from the manufacturer.\n## 10.7.4 Recording and Follow-Up of Medical Device AE and/or\n## SAE and Device Deficiencies\n## 10.7.4.1 Medical Device AE, SAE, and Device Deficiency Recording\nThe investigator will record all relevant AE/SAE/device deficiency information in the\nparticipant’s medical records and on the appropriate form. For device deficiencies, any\ncorrective or remedial actions taken must be described.\n## 10.7.4.2 Assessment of Intensity\nIntensity will be assessed as Mild, Moderate, or Severe.\n## 10.7.4.3 Assessment of Causality\nThe investigator will assess the relationship between the study device and each event,\nusing clinical judgment and consulting the investigator’s brochure or instructions for use.\n## 10.7.4.4 Follow-up of Medical Device AE/SAE and device deficiency\nThe investigator will perform supplemental evaluations as needed to elucidate the nature\nand causality of the event. Updated information will be recorded and submitted to the\nsponsor promptly.\n## 10.7.5 Reporting of Medical Device SAEs\nSAEs will be reported to the sponsor within 24 hours, primarily via an electronic data\ncollection tool, with a paper-based system as a backup.\n•\n•\n•\n•\n•\n•\n•\n## 10.7.6 Reporting of SADEs\nAny device deficiency associated with an SAE must be reported to the sponsor within 24\nhours. The sponsor will review these events and report them to regulatory authorities and\nIRBs/IECs as required.\n# 10.8 Appendix 8: Country-specific Requirements\nThis appendix will detail any country-specific requirements or regional regulatory adaptations\nthat cannot be addressed by flexible language within the main body of the protocol.\n# 10.9 Appendix 9: Protocol Amendment History\nThe Protocol Amendment Summary of Changes Table for the current amendment will be located\nbefore the table of contents. This appendix will contain the history of all previous amendments.\nAmendments will be classified as substantial or non-substantial based on criteria set forth in\nregulations such as EU No 536/2014. The rationale for changes will be documented, and a clear\nnumbering system for global, country-specific, and site-specific amendments will be maintained.\n# 10.10 References\n(2022). Survey Provides Updated Definitions of Platinum-Ineligible Patients With Bladder\nCancer.\nDefault Digital Object Group\n. https://doi.org/10.1200/adn.22.200975\n(2025). Chronic Kidney Disease and Anemia: Exploring Patterns with Creatinine Clearance\n<30 mL/min/1.73 m².\nJournal of Pakistan Society of Internal Medicine\n. https://doi.org/\n10.70302/jpsim.v6i2.2526\nLu, G., Lin, J. P., Bui, K., Curnutte, J. T., & Conley, P. B. (2019). Prothrombin Complex\nConcentrates (PCCs) Have Limited Effect on TF-Initiated Thrombin Generation in FXa\nInhibitor-Anticoagulated Plasma: In Vitro Comparison between Direct Reversal By\nAndexanet Alfa and ‘Work Around’ By PCCs.\nBlood\n. https://doi.org/10.1182/\nblood-2019-124864\nPathan, S. (2024). Co-administration of Four-Factor Prothrombin Complex Concentrate\nWith Andexanet alfa for Reversal of Nontraumatic Intracranial Hemorrhage.\nHospital\nPharmacy\n. https://doi.org/10.1177/00185787241229192\nAhn, H.-S., Chae, H., Kim, Y., Lee, H., & Kim, H. (2024). Heparin-Calibrated Anti-Factor Xa\nAssay for the Measurement of Direct Anticoagulants such as Apixaban, Rivaroxaban, and\nEdoxaban.\nClinical Laboratory\n. https://doi.org/10.7754/clin.lab.2024.240314\n•\n1.\n2.\n3.\n4.\n5.\nRiahi, N., Rozen, L., & Demulder, A. (2023). Usefullness of Heparin Calibrated Anti-Xa\nActivity to Assess Anticoagulant Activity of Apixaban and Rivaroxaban in Emergency\nPatients Scheduled for Acute Interventions.\nJournal of Clinical Medicine\n. https://doi.org/\n10.3390/jcm12216785\nLin, C. A., & Pujari, A. (2019). Targeted Dosing of Low Molecular-Weight Heparin (LMWH)\nfor Deep Vein Thrombosis (DVT) Prophylaxis in Orthopaedic Trauma Patients Does Not\nReduce Thromboembolic Events. . https://doi.org/10.26226/\nmorressier.5cffabadf6074e97f94aadba\n(2022). Direct Oral Anticoagulants Have Lower Intracranial Hemorrhage Rates in\nGlioblastoma Compared With Low Molecular Weight Heparin.\nDefault Digital Object Group\n.\nhttps://doi.org/10.1200/adn.22.200966\n(2021). Introduction to Multiple Testing and Methods for Error Rate Control. . https://doi.org/\n10.4135/9781529778205\nVoelkl, B. (2019). Multiple testing: correcting for alpha error inflation with false discovery\nrate (FDR) or family-wise error rate?\nAnimal Behaviour\n. https://doi.org/10.1016/\nj.anbehav.2019.07.001\nMeneely, P. (2020). Genome-wide mutant screens.\nGenetic Analysis\n. https://doi.org/\n10.1093/hesc/9780198809906.003.0011\nLi, J. H., Brenner, L. N., Kaur, V., Figueroa, K., Udler, M. S., Leong, A., MAGIC\nInvestigators, Mercader, J. M., & Florez, J. C. (2022). Genome-wide association analysis\nidentifies ancestry-specific genetic variation associated with medication response in the\nStudy to Understand the Genetics of the Acute Response to Metformin and Glipizide in\nHumans (SUGAR-MGH). . https://doi.org/10.1101/2022.01.24.22269036\n6.\n7.\n8.\n9.\n10.\n11.\n12.",
    "context": "MANDATORY SPONSOR INPUTS FOR STUDY PROTOCOL GENERATION\nSponsor Name FADOI /BMS/PFIZER\nStudy Acronym (if available):  CARAVAGGIO Study\nTested IMP :Apixaban\nComparative drug: Dalteparin\nStudy Type Interventional\nSe Study Type = Interventional:\nInterventional Study Phase Phase IIIb\nStudy Design International, multicenter, Prospective Randomized Open Blinded End-point (PROBE), where both patients and investigators are aware of the treatment assignments, but the outcome assessment is blindedactive-controlled, event-driven, Phase IIIB clinical study comparing the efficacy and safety of Apixaban to the SOC Dalteparin in for the treatment of venous thromboembolism in patients with cancer.\nAim of the study: The aim of this study is to assess whether oral apixaban is non-inferior to the subcutaneous low molecular weight (LMWH) dalteparin for the treatment of newly diagnosed proximal deep vein thrombosis (DVT) and/or pulmonary embolism (PE) in patients with cancer.\nTarget Disease: VTE (DVT/PE) in cancer patients\nType of Randomization: Patients will be randomized on a 1:1 basis (permuted blocks of four) to receive either apixaban or dalteparin in an open-label fashion.\nRandomization should be centralized and stratified by:\n1) symptomatic vs. unsuspected VTE\n2) active cancer vs. history of cancer\nTested drugs and dosages \nApixaban group: orally administered, at the dose of 10 mg bid for 7 days, followed by 5 mg bid (total period of treatment: six months)\nDalteparin group: subcutaneously administered, at a dose of 200 IU/kg SC o.i.d for 1 month. Thereafter, dalteparin will be administered at a dose of 150 IU/kg o.i.d. for 5 months (total period of treatment: six months). The maximum daily dose allowed for dalteparin is 18,000IU.\nApixaban 5mg will be supplied by the Promoter as film-coated tablets.\nDalteparin will be supplied by the Promoter as single-use pre-filled syringes.\nStudy Scheduled Patient’s Visits\nThe study should foresee the following scheduled visits: at enrollment, at 4 weeks, at 3 months, at 6 months, at the end of study treatment whenever it occurs, and at 7 months from randomization.\nAdditional visits will be performed if new symptoms and/or signs of VTE or major bleeding develop. A clinical examination and objective tests will be performed if the patient develops symptoms or signs suggestive of recurrent VTE.\nStudy Objectives \nPrimary efficacy outcome:\nobjectively confirmed recurrent VTE occurring during the study period, that means the composite of:\n• proximal DVT of the lower limbs (symptomatic or unsuspected)\n• DVT of the upper limb (symptomatic)\n• PE (symptomatic or unsuspected)\nSecondary efficacy outcomes:\n• the individual components of the primary efficacy outcome;\n• symptomatic recurrence of VTE;\n• all cause death;\n• the composite of primary efficacy outcome plus major bleeding;\n• the composite of primary efficacy outcome plus major bleeding plus all cause death;\n• the composite of primary efficacy outcome plus all cause death;\n• any major cardiovascular event, fatal or non-fatal (including acute myocardial infarction or ischemic stroke);\n• all venous thromboembolic events (including splanchnic vein thrombosis and cerebral vein thrombosis);\n• Quality of life (QoL) according to Anti-Clot Treatment Scale (ACTS) \nSafety Study Outcomes:\nPrimary safety outcome is major bleeding, defined (as per ISTH guidelines), as acute clinically overt bleeding associated with one or more of the following:\n• decrease in hemoglobin of 2 g/dl (1.2 mmol/L) or more;\n• transfusion of 2 or more units of packed red blood cells;\n• bleeding that occurs in at least one critical site [intracranial, intra-spinal, intraocular (within the corpus of the eye; thus, a conjunctival bleed is not an intraocular bleed), pericardial, intra-articular, intramuscular with compartment syndrome, or retroperitoneal];\n• bleeding that is fatal;\n• bleeding that necessitates acute surgical intervention\nSecondary safety outcomes include:\n• Clinically relevant non-major bleeding event defined as acute clinically overt bleeding that does not meet the criteria for major and consists of:\n• any bleeding compromising hemodynamics;\n• spontaneous hematoma larger than 25 cm2, or 100 cm2 if there was a traumatic cause;\n• intramuscular hematoma documented by ultrasonography;\n• epistaxis or gingival bleeding requiring tamponade or other medical intervention or bleeding from venipuncture for >5 minutes;\n• hematuria that was macroscopic and was spontaneous or lasted for more than 24 hours after invasive procedures;\n• hemoptysis, hematemesis or spontaneous rectal bleeding requiring endoscopy or other medical intervention;\n• or any other bleeding considered to have clinical consequences for a patient such as medical intervention,\nthe need for unscheduled contact (visit or telephone call) with a physician, or temporary cessation of a study drug, or associated with pain or impairment of activities of daily life.\n• Clinically relevant bleeding defined as the composite of major and clinically relevant non-major bleeding\n• Permanent early discontinuation of study drug due to safety reasons\nMaximum Sample Size for each arm\nLess than 600 patients for each treatment group\nRecommended Inclusion Criteria\nAge > 18 years\nBoth Genders\nSigned Informed Consent\nConsecutive patients with a newly diagnosed, objectively\nconfirmed:\n• symptomatic or unsuspected, proximal lower-limb DVT\nor\n• symptomatic PE or\n• unsuspected PE in a segmental or more proximal pulmonary artery.\nAny type of cancer (other than basal-cell or squamous-cell carcinoma of the skin, primary brain tumor or known intracerebral metastases and acute leukemia) that meets at least one of the\nfollowing:\n• Active cancer defined as diagnosis of cancer within six months before the study inclusion, or receiving treatment for cancer at the time of inclusion or any treatment for cancer during 6 months prior to randomization, or recurrent locally advanced or metastatic cancer.\n• Cancer diagnosed within 2 years before the study inclusion (history of cancer).\nRecommended Exclusion Criteria\nage <18 years\nECOG Performance Status III or IV;\nlife expectancy of less than 6 months;\nrelated to anticoagulant treatment:\nadministration of therapeutic doses of LMWH, fondaparinux, or unfractionated heparin (UFH) for more than 72 hours before randomization;\n3 or more doses of a vitamin K antagonist before randomization;\nthrombectomy, vena cava filter insertion, or thrombolysis used to manage the index episode;\n indication for anticoagulant treatment for a disease other than the index VTE episode;\nconcomitant use of strong inhibitors or inducers of both cytochrome P-450 3A4 and P-Glycoprotein ;\nrelated to bleeding risk:\nconcomitant thienopyridine therapy (clopidogrel, prasugrel, or ticagrelor) or aspirin over 165 mg daily or dual antiplatelet therapy;\nactive bleeding or high risk of bleeding contraindicating anticoagulant treatment\nrecent (in the last 1 month prior to randomization) brain, spinal or ophthalmic surgery\n hemoglobin level lower than 8 g/dL (5.0 mmol/L) or platelet count <75x109/L or history of heparin-induced thrombocytopenia;\ncreatinine clearance < 30 ml /min based on the Cockcroft Gault equation;\nacute hepatitis, chronic active hepatitis, liver cirrhosis; or an alanine aminotransferase level 3 times or more and/or bilirubin level 2 times or more higher the upper limit of the normal range;\nuncontrolled hypertension (systolic BP> 180 mm Hg or diastolic BP > 100 mm Hg despite antihypertensive treatment);\nstandard criteria:\n bacterial endocarditis;\nhypersensitivity to the study drugs or to any of their excipients;\npatients participation in other pharmaco therapeutic program with an experimental therapy that is known to effect the coagulation system.\nwomen of childbearing potential (WOCBP) who do not practice a medically accepted highly effective contraception during the trial and one month beyond. Highly effective contraception methods are:\na. combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation\nb. progestogen-only hormonal contraception associated with inhibition of ovulation\nc. intrauterine device (IUD)\nd. intrauterine hormone-releasing system (IUS)\ne. bilateral tubal occlusion\nf. vasectomized partner\ng. sexual abstinence ;\npregnancy, or breast feeding\nany condition that, as judged by the investigator, would place the subject at increased risk of harm if he/she participated in the study.\n"
}